A Phase 1b/2 Study of Tergenpumatucel-L (HyperAcute Lung) Immunotherapy in Combination With the IDO Pathway Inhibitor Indoximod and Docetaxel in Patients With Advanced Previously Treated Non-Small Cell Lung Cancer (NSCLS)

Trial Profile

A Phase 1b/2 Study of Tergenpumatucel-L (HyperAcute Lung) Immunotherapy in Combination With the IDO Pathway Inhibitor Indoximod and Docetaxel in Patients With Advanced Previously Treated Non-Small Cell Lung Cancer (NSCLS)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Feb 2016

At a glance

  • Drugs Tergenpumatucel-L (Primary) ; Docetaxel; Indoximod
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NewLink Genetics Corporation
  • Most Recent Events

    • 02 Feb 2016 According to CT.gov record, phase of the trial changed from phase II to phase I/II, official title changed.Also,safety is now included as primary endpoint,treatment arms changed from 1 to 2,planned patient number changed from 59 to 115 and treatment section revised with changes in frequency of drugs administration(i.e.for Tergenpumatucel-L- frequency changed from q2w total 24 doses to q3w total 18 doses for Indoximod it changed from BID to TID).
    • 02 Feb 2016 Planned number of patients changed from 59 to 115, as reported by ClinicalTrials.gov.
    • 03 Nov 2015 According to a NewLink Genetics Corporation media release, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top